Alnylam Pharmaceuticals, Inc.
ALNY
|
$147.7
-0.54%
-0.49%
500K
|
Health Technology
(0.0% 1d) (0.2% 1m) (-28.3% 1y) (0.0% 2d) (0.0% 3d) (-3.1% 7d) (16.56% volume)
Earnings Calendar: 2024-02-15
Market Cap: $ 18,602,193,626
http://www.alnylam.com
Sec Filling | Patents | 1323 employees
(US) Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
glass genetic msa treatment
Drugs
GIVLAARI (givosiran sodium)Onpattro (patisiran)
OXLUMO (lumasiran)
add to watch list Paper trade email alert is off
Press-releases
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Published: 2024-03-20 (Crawled : 13:00) - biospace.com/
ALNY | $147.7 -0.54% -0.49% 500K
|
Health Technology
|
| O: -0.11%
H: 0.43%
C: -0.01%
cardiology results study
Rapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of Directors
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
ALNY | $147.7 -0.54% -0.49% 500K
|
Health Technology
|
| O: -0.33%
H: 1.88%
C: 0.84%
therapeutics
Zenas BioPharma Appoints Patricia Allen to its Board of Directors
Published: 2024-03-06 (Crawled : 16:00) - biospace.com/
ALNY | $147.7 -0.54% -0.49% 500K
|
Health Technology
|
| O: 0.31%
H: 0.06%
C: -0.33%
biopharma
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
ALNY | $147.7 -0.54% -0.49% 500K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
positive blood care topline results study
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
Published: 2024-03-05 (Crawled : 15:30) - biospace.com/
VIR | $8.55 -4.68% -4.91% 770K
|
Health Technology
|
| O: -0.09%
H: 2.06%
C: -2.68%
ALNY | $147.7 -0.54% -0.49% 500K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
hepatitis trial
Alnylam to Webcast Presentations at Upcoming March Investor Conferences - February 27, 2024
Published: 2024-02-27 (Crawled : 14:00) - biospace.com/
ALNY | $147.7 -0.54% -0.49% 500K
|
Health Technology
|
| O: 0.84%
H: 0.82%
C: -0.63%
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-22 (Crawled : 00:00) - biospace.com/
XNCR | $20.09 -1.9% -1.94% 390K
|
Health Technology
|
| O: -0.87%
H: 2.89%
C: 2.14%
VIR | $8.55 -4.68% -4.91% 770K
|
Health Technology
|
| O: -0.69%
H: 2.99%
C: 2.59%
ALNY | $147.7 -0.54% -0.49% 500K
|
Health Technology
|
| O: -0.17%
H: 6.18%
C: 5.4%
year update financial results
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Published: 2024-02-15 (Crawled : 14:30) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
ALNY | $147.7 -0.54% -0.49% 500K
|
Health Technology
|
| O: -8.62%
H: 2.18%
C: -1.71%
year pharmaceuticals financial results
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | $9.2715 -2.92% -1.11% 500K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | $161.67 -0.38% -0.14% 3.4M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
GILD | $67.76 -1.3% -1.31% 7.7M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
ALNY | $147.7 -0.54% -0.49% 500K
|
Health Technology
|
| O: -2.63%
H: 0.98%
C: -1.75%
liver disease therapeutics market
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
TSVT | $4.985 -1.09% -1.1% 390K
|
|
| O: -1.16%
H: 9.94%
C: 2.34%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 1.4%
H: 0.28%
C: -2.68%
ALNY | $147.7 -0.54% -0.49% 500K
|
Health Technology
|
| O: -1.23%
H: 1.0%
C: 0.17%
year financial results
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
EEIQ | $1.15 26.36% 20.86% 7.6K
|
Educational Services
Last 48 Hours Insiders Buying
RMCF | $3.56 -7.2% 7.1K
|
Consumer Non-Durables
|
20:10